Efficacy of Polypodium Leucotomos Extract Decreasing UVA Premutagenic and Photoaging Markers

Single-Blind Study Determining the Efficacy of Polypodium Leucotomos Extract Supplement in Decreasing UVA Premutagenic and Photoaging Markers

With this study, the investigators will like to determine if taking a dose of the study medication, called Polypodium leucotomos (PL), prevents some of the changes in the skin caused by the adverse effects of UVA, a type of ultraviolet light.

Inclusion Criteria:

• Healthy subjects,
• 18 years of age or older,
• with Fitzpatrick skin types II and III.

Exclusion Criteria:

• Pregnancy
• Personal history of skin cancer
• History of abnormal photosensitivity
• Smokers
• Patients with history or being exposed to other forms of radiation (other than sunlight)
• History or current exposure to asbestos
• Patients taking any drug that might alter the response of skin to UVR (including, but are not limited to, doxycycline, sulfas, psoralens, and amiodarone)
• Patients unable to undergo skin biopsies
• History of abnormal scarring
• History of adverse reaction to local anesthesia